



General description

Testicular germ cell tumour  Ovarian germ cell tumour  Osteosarcoma  Rhabdomyosarcoma  Ewing sarcoma.

INN	Mesna
ATC codes	V03AF01
Medicine type	Chemical agent
EML status history	<p>First added in 2009 (TRS 958) for Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Added in 2015 (TRS 994) for Osteosarcoma of bone and articular cartilage of other specified sites</p> <p>Added in 2015 (TRS 994) for Rhabdomyosarcoma primary site</p> <p>Added in 2015 (TRS 994) for Other specified malignant neoplasms of the ovary</p> <p>Added in 2015 (TRS 994) for Germ cell tumour of testis</p> <p>Added in 2015 (TRS 994) for Ewing sarcoma of bone and articular cartilage of unspecified sites</p> <p>Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Added in 2021 (TRS 1035) for Burkitt lymphoma including Burkitt leukaemia</p> <p>Added in 2021 (TRS 1035) for Malignant neoplasms of kidney, except renal pelvis</p>
Wikipedia	Mesna 
DrugBank	Mesna (Coenzyme M) 

Recommendations

Section Supportive medicines

Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
 Oral > Solid: 400 mg; 600 mg

Indications

Osteosarcoma of bone and articular cartilage of other specified sites

Rhabdomyosarcoma primary site

Other specified malignant neoplasms of the ovary

Germ cell tumour of testis

Ewing sarcoma of bone and articular cartilage of unspecified sites

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Malignant neoplasms of kidney, except renal pelvis

